China
Africa
Explore chapters and articles related to this topic
Cancer and exercise
Published in Adam P. Sharples, James P. Morton, Henning Wackerhage, Molecular Exercise Physiology, 2022
Tormod S. Nilsen, Pernille Hojman, Henning Wackerhage
Cancer is a relatively common disease with improving but still imperfect treatment. According to the World Health Organization, 18.1 million new cancer cases were diagnosed worldwide in 2018, and an estimated 9.6 million people died from cancer. Roughly 50% of patients survive cancer for ten years, but this differs markedly between cancer types, with testicular cancer having the highest and pancreatic cancer having the lowest survival rates. Breast, prostate, lung and colon (bowel) cancers are the most common cancers in the UK and most Western countries as they account for roughly half of all cancers (1).
The Infertile Male
Published in Arianna D'Angelo, Nazar N. Amso, Ultrasound in Assisted Reproduction and Early Pregnancy, 2020
Thoraya Ammar, C. Jason Wilkins, Dean C.Y. Huang, Paul S. Sidhu
Men with infertility have an increased risk of testicular cancer, even after excluding the common risk factors for testicular cancer and infertility, such as a history of undescended testes and chromosomal aberrations.
Testicular cancer
Published in Anju Sahdev, Sarah J. Vinnicombe, Husband & Reznek's Imaging in Oncology, 2020
The management of GCT depends on the pathology, staging, and prognostic grouping of the tumour. Treatment guidelines and reviews of the management of testicular cancer have been published (10,13,15), and the following is a brief summary in order to understand the role of imaging.
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?
Published in Expert Review of Anticancer Therapy, 2023
Patients with stage 1 disease now form most cases. The risk factors for recurrence of testicular cancer (including lymphovascular invasion, size, and involvement of the rete testis) as well as the relative benefits of chemotherapy are well established. Efforts to de-escalate treatment while preserving efficacy have been successful in this disease setting. One cycle of BEP is considered the standard adjuvant chemotherapy in high-risk stage I non-seminoma, following a series of randomized clinical trials, the most recent being the 111 study [8]. One course of carboplatin AUC7 is considered standard adjuvant chemotherapy in stage I seminoma [9]. In patients at low risk of recurrence, chemotherapy can still be offered, but patient autonomy must be taken into account following the provision of thorough information regarding the relative benefits and disadvantages of alternative management strategies. We focus predominantly on patients with metastatic germ cell tumors by virtue of cumulative toxicity. Any discussion focused on Stage 1 disease will be explicitly highlighted.
Cancer in the Faroe Islands from 1960-2019 – incidence, mortality, and comparisons with the other Nordic countries
Published in Acta Oncologica, 2022
Marnar F. Kristiansen, Ronja M. Mikkelsen, Tordis Kristiansdóttir, Páll Rasmussen, Guðrið Andórsdóttir, Sæunn Ó. Hansen, Kári R. Nielsen, Bjarni á Steig, Marin Strøm, Maria Skaalum Petersen
In the present study, we show that some cancers were more common in the Faroe Islands compared to the Nordic countries. A graphical presentation of these trends can be on the NORDCAN website [20]. Among these cancers, testicular cancer stands out, with an especially steep increase in the Faroe Islands over the last 20 years, with rates more than doubling during this time. Testicular cancer is the most common cancer in young males, and the incidence of testicular cancer has increased elsewhere as well, as the incidence has doubled over the past 40 years, with the highest increases observed in Western countries [24]. Luckily, testicular cancer has a very high survival, but treatment is not without risk or long-term consequences for the men who survive [25]. There are several known risk factors for testicular cancer, including cryptorchidism, decreased spermatogenesis, infections, and prenatal and postnatal exposure to chemicals [26–28].
The experience of financial stress among emerging adult cancer survivors
Published in Journal of Psychosocial Oncology, 2020
Sugandha K. Gupta, Mary Carol Mazza, Michael A. Hoyt, Tracey A. Revenson
The developmental tasks of emerging adulthood may be interrupted by the “off-time” nature of a cancer diagnosis at this life stage.18 A cancer diagnosis in emerging adulthood is particularly unexpected and fewer age peers are facing the same issues, leading to an overall lack of support.19 Thus, how cancer-related financial stress affects EA cancer survivors may be distinct to this (as to any) developmental life stage and affect quality of life in unique ways. The current study adopts this psychological lens of developmental context to understand how EA cancer survivors experience cancer-related financial stress. This premise is explored with data from survivors of two commonly diagnosed cancers among young adults: testicular cancer and hematologic (blood) cancers. These two cancers have comparable and relatively high survival rates among adults younger than 45, ranging from 60.4% (acute myeloid leukemia) to 95.6% (testicular cancer).20